Hypoxia-targeted siRNA delivery

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Tumor hypoxia, characterized by low oxygen levels, is a significant challenge in cancer therapy, contributing to treatment resistance.
• Poor drug delivery to hypoxic tumor regions is a major cause of therapeutic failure.
• Existing strategies like hypoxia imaging agents and prodrugs aim to overcome these limitations.

Purpose of the Study:

• To demonstrate the first example of hypoxia-induced siRNA delivery and gene silencing using a novel nanocarrier.
• To develop a tumor-environment-responsive system for targeted cancer therapy.
• To investigate the potential of this nanocarrier for enhanced therapeutic agent delivery.

Main Methods:

• A unique nanocarrier (PAPD) was synthesized using polyethyleneglycol, azobenzene, polyethyleneimine (PEI), and DOPE.
• The nanocarrier's azobenzene component confers hypoxia sensitivity and specificity.
• In vitro and in vivo experiments were conducted to assess siRNA uptake and gene silencing in hypoxic conditions and GFP-expressing tumors.

Main Results:

• The nanocarrier successfully facilitated hypoxia-induced siRNA uptake and gene silencing in vitro.
• Downregulation of green fluorescent protein (GFP) was observed in GFP-expressing tumors following intravenous administration of the nanocarrier.
• The azobenzene moiety ensured specific targeting and activation in the hypoxic tumor microenvironment.

Conclusions:

• The developed PAPD nanocarrier represents a novel platform for hypoxia-targeted siRNA delivery.
• This approach offers a promising strategy for overcoming therapeutic resistance associated with tumor hypoxia.
• The nanoformulation demonstrates potential as a tumor-environment-responsive modality for advanced cancer treatment.